Plasma N-terminal Prosomatostatin and Risk of Incident Cardiovascular Disease and All-Cause Mortality in a Prospective Observational Cohort: the PREVEND Study

Ali Abbasi, Lyanne M. Kieneker, Eva Corpeleijn, Ron T. Gansevoort, Rijk O. B. Gans, Joachim Struck, Rudolf A. de Boer, Hans L. Hillege, Ronald P. Stolk, Gerjan Navis, Stephan J. L. Bakker

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)

Abstract

BACKGROUND: Somatostatin is a component of the well-known insulin-like growth factor-1growth hormone (GH) longevity axis. There is observational evidence that increased GH is associated with an increased risk of cardiovascular disease (CVD). We aimed to investigate the potential association of plasma N-terminal fragment prosomatostatin (NT-proSST) with incident CVD and all-cause mortality in apparently healthy adults.METHODS: We studied 8134 participants without history of CVD (aged 28-75 years; women, 52.6%) from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study in Groningen, the Netherlands. Plasma NT-proSST was measured in baseline samples. Outcomes were incidence of CVD and all-cause mortality.RESULTS: In cross-sectional analyses, NT-proSST [mean (SD), 384.0 (169.3) pmol/L] was positively associated with male sex and age (both P
Original languageEnglish
Pages (from-to)278-287
Number of pages10
JournalClinical Chemistry
Volume63
Issue number1
DOIs
Publication statusPublished - Jan 2017
Externally publishedYes

Bibliographical note

© 2016 American Association for Clinical Chemistry.

Fingerprint

Dive into the research topics of 'Plasma N-terminal Prosomatostatin and Risk of Incident Cardiovascular Disease and All-Cause Mortality in a Prospective Observational Cohort: the PREVEND Study'. Together they form a unique fingerprint.

Cite this